Using our DECS technology platform, we extract the best from drugs to deliver new, best-in-class medicines.
Through a combination of site-specific deuteration and chiral chemistry, we are creating superior drugs that target fundamental elements of neurological diseases like Major Depressive Disorder (MDD).
We are developing novel, patent-protected NCEs with superior activity and/or tolerability profiles utilizing the 505(b)(2) regulatory pathway to expedite and de-risk approval.
Neuromity Therapeutics, Inc. is a Boston-based biopharmaceutical company dedicated to making better drugs for serious neurological disorders.
Our patent-protected lead drug candidate, NTY-184, is based on bupropion, the active ingredient in the widely-prescribed antidepressant, Wellbutrin®. In pre-clinical studies, NTY-184 has a better activity profile and tolerability compared to bupropion. With FDA's guidance, we have defined an expeditious and de-risked path to approval for Major Depressive Disorder (MDD).